Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma

11 Aug 2020

Abstract excerpt

Concomitant deregulation of MYC and BCL2 comprises clinically significant, yet poorly characterized biological high-risk feature in diffuse large B-cell lymphoma (DLBCL). To interrogate these lymphomas, we analyzed translocations and protein expression of BCL2, BCL6, and MYC; correlated the findings with comprehensive mutational, transcriptomic, and clinical data in 181 patients with primary DLBCL; and validated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CNS Lymphoma Diagnosis and Treatment
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32780847
DOI: 10.1182/bloodadvances.2020001727

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphomaPMID 32780847Read ↗

The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Semantic proximity Read ↗

The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era.Semantic proximity Read ↗

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?Semantic proximity Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.Semantic proximity Read ↗

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.Semantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.Semantic proximity Read ↗

High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.Semantic proximity Read ↗

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].Semantic proximity Read ↗

Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.